During its June 2026 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency completed its review of a safety signal for valproate and related substances and recommended New safety information for healthcare professionals regarding the chikungunya vaccine Ixchiq.
FAMHP (Belgian Medicine Agency)
PRAC June 2026: safety signal review for valproate and new safety information for Ixchiq chikungunya vaccine
Original title: PRAC June 2026: completed review of a safety signal for valproate and related substances and recommended new safety information for healthcare professionals regarding the chikungunya vaccine Ixchiq
EMA PRAC completed review of valproate safety signal and recommended new safety information for Ixchiq chikungunya vaccine.
Published by FAMHP (Belgian Medicine Agency). HealthSignal links to the original document; the summary above is extracted from the source text.